| Literature DB >> 31807198 |
Heather J Lacey1,2, Cameron L M Gilchrist3, Andrew Crombie1, John A Kalaitzis1,4, Daniel Vuong1, Peter J Rutledge2, Peter Turner2, John I Pitt1, Ernest Lacey1,4, Yit-Heng Chooi3, Andrew M Piggott4.
Abstract
Chemical investigation of an undescribed Australian fungus, Aspergillus nanangensis, led to the identification of the nanangenines - a family of seven new and three previously reported drimane sesquiterpenoids. The structures of the nanangenines were elucidated by detailed spectroscopic analysis supported by single crystal X-ray diffraction studies. The compounds were assayed for in vitro activity against bacteria, fungi, mammalian cells and plants. Bioinformatics analysis, including comparative analysis with other acyl drimenol-producing Aspergilli, led to the identification of a putative nanangenine biosynthetic gene cluster that corresponds to the proposed biosynthetic pathway for nanangenines.Entities:
Keywords: Aspergillus; biosynthesis; drimane; secondary metabolites; sesquiterpenoid; terpenes
Year: 2019 PMID: 31807198 PMCID: PMC6880815 DOI: 10.3762/bjoc.15.256
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Structures of nanangenines 1–10 isolated from A. nanangensis.
NMR data for nanangenine A (1) in DMSO-d6.
| Position | δCa | δH, mult. ( |
| 1 | 69.0 | 4.12, dd (8.4, 7.8) |
| 2 | 26.2 | 1.54, m |
| 3 | 41.5 | 1.22, m |
| 4 | 33.6 | |
| 5 | 45.0 | 1.52, d (5.0) |
| 6 | 63.3 | 4.30, m |
| 7 | 128.2 | 5.92, m |
| 8 | 131.1 | |
| 9 | 76.1 | |
| 10 | 42.4 | |
| 11 | 179.3 | |
| 12a | 70.6 | 5.00, ddd (12.2, 2.5, 2.4) |
| 12b | 4.91, ddd (12.2, 1.3, 1.2) | |
| 13 | 12.6 | 0.92, s |
| 14 | 24.3 | 1.23, s |
| 15 | 31.9 | 1.02, s |
| 1-OH | 4.76, s | |
| 6-OH | 4.81, br d (5.8) | |
| 9-OH | 6.50, s | |
aAcquired at 125 MHz; bacquired at 500 MHz.
NMR data for nanangenine D (5), isonanangenine D (6) and nanangenine E (7) in DMSO-d6.
| Position | Nanangenine D ( | Isonanangenine D ( | Nanangenine E ( | |||
| δCa | δH, mult. ( | δCa | δH, mult. ( | δCa | δH, mult. ( | |
| 1a | 68.7 | 4.17, ddd (10.9, 5.9, 0.9) | 68.6 | 3.95, ddd (12.0, 5.9, 3.9) | 29.4 | 1.95, ddd (15.0, 13.5, 4.3) |
| 1b | 1.81, dm (13.5) | |||||
| 2a | 25.9 | 1.57, m | 27.2 | 1.53, m | 17.4 | 1.59, m |
| 2b | 1.47, m | |||||
| 3a | 41.3 | 1.28, m | 41.7 | 1.31, ddd (13.3, 3.5, 3.5) | 44.3 | 1.33, dm (13.0) |
| 3b | 1.23, m | 1.19, m | ||||
| 4 | 33.1 | 32.9 | 33.3 | |||
| 5 | 43.8 | 1.87, d (4.9) | 44.1 | 1.99, d (5.2) | 44.0 | 1.97, d (4.9) |
| 6 | 66.0 | 5.46, m | 66.0 | 5.59, dd (5.1, 3.9) | 66.0 | 5.47, m |
| 7 | 121.9 | 5.88, m | 131.6 | 6.45, d (3.9) | 121.3 | 5.77, m |
| 8 | 135.5 | 133.2 | 136.5 | |||
| 9 | 75.6 | 75.0 | 73.1 | |||
| 10 | 42.4 | 43.2 | 37.2 | |||
| 11a | 178.4 | 76.4 | 4.41, dd (10.2, 0.5) | 174.3 | ||
| 11b | 4.19, br d (10.2) | |||||
| 12a | 70.3 | 5.03, ddd (12.8, 4.8, 2.5) | 168.6 | 68.2 | 4.87, ddd (12.8, 2.5, 2.5) | |
| 12b | 4.94, ddd (12.8, 1.7, 1.2) | 4.74, ddd (12.8, 1.2, 1.2) | ||||
| 13 | 12.2 | 0.94, s | 12.3 | 0.94, s | 18.1 | 0.99, s |
| 14 | 24.0 | 1.06, s | 24.2 | 1.08, s | 24.2 | 1.08, s |
| 15 | 31.5 | 0.90, s | 31.9 | 0.91, s | 32.1 | 0.91, s |
| 1' | 172.2 | 172.2 | 172.2 | |||
| 2'a | 34.0 | 2.33, m | 33.9 | 2.36, m | 34.0 | 2.32, m |
| 2'b | 2.27, m | 2.27, m | 2.25, m | |||
| 3' | 24.2 | 1.53, m | 24.2 | 1.53, m | 24.2 | 1.52, m |
| 4' | 28.2 | 1.24, m | 28.2 | 1.23, m | 28.3 | 1.24, m |
| 5' | 28.3 | 1.24, m | 28.2 | 1.23, m | 28.2 | 1.24, m |
| 6' | 31.0 | 1.22, m | 31.0 | 1.21, m | 31.0 | 1.21, m |
| 7' | 21.9 | 1.24, m | 21.9 | 1.23, m | 21.9 | 1.24, m |
| 8' | 13.9 | 0.84, t (7.9) | 13.9 | 0.83, t (7.2) | 13.9 | 0.84, t (7.2) |
| 1-OH | 4.71, d (0.9) | 4.62, d (5.1) | – | |||
| 9-OH | 6.77 s | 5.61 br s | 6.24 s | |||
aAcquired at 150 MHz; bacquired at 600 MHz.
NMR data for nanangenines F-H (8–10) in DMSO-d6.
| Position | Nanangenine F ( | Nanangenine G ( | Nanangenine H ( | |||
| δCa | δH, mult. ( | δCc | δH, mult. ( | δCa | δH, mult. ( | |
| 1 | 68.5 | 3.88, ddd (11.9, 5.8, 5.8) | 69.1 | 3.93 dd (11.2, 4.3) | 68.4 | 3.93, ddd (11.8, 5.4, 5.0) |
| 2a | 27.3 | 1.51, m | 28.3 | 1.56, m | 27.5 | 1.53, m |
| 2b | 1.47, m | 1.48, m | ||||
| 3a | 41.6 | 1.26, m | 41.6 | 1.23, m | 41.9 | 1.27, m |
| 3b | 1.21, m | 1.22, m | ||||
| 4 | 32.8 | 33.5 | 32.8 | |||
| 5 | 43.5 | 1.84, d (4.7) | 44.9 | 1.83, d (4.4) | 44.3 | 1.95, d (4.0) |
| 6 | 66.5 | 5.37, m | 67.0 | 5.41, m | 67.1 | 5.46, ddd (5.0, 3.9, 1.4) |
| 7 | 124.0 | 5.53, dq (5.1, 1.5) | 121.4 | 5.78, br d (5.3) | 120.3 | 5.57, dd (3.9,1.4) |
| 8 | 137.2 | 144.1 | 145.0 | |||
| 9 | 80.1 | 75.6 | 78.3 | |||
| 10 | 47.0 | 45.9 | 43.5 | |||
| 11a | 203.3 | 9.49, br s | 62.2 | 3.73, m | 74.5 | 3.84, d (9.7) |
| 11b | 3.67, m | 3.76, d (9.7) | ||||
| 12a | 19.5 | 1.51, dd, (1.3, 1.3) | 61.0 | 4.05, m | 101.9 | 5.31, t (1.4) |
| 12b | 4.02, m | |||||
| 13 | 11.5 | 1.06, s | 12.5 | 1.06, s | 11.7 | 0.92, s |
| 14 | 24.3 | 1.05, s | 24.4 | 1.03, s | 24.3 | 1.08, s |
| 15 | 31.8 | 0.89, s | 32.4 | 0.87, br s | 32.1 | 0.89, s |
| 1' | 172.3 | 172.7 | 172.3 | |||
| 2'a | 34.1 | 2.30, m | 34.5 | 2.24, m | 34.1 | 2.32, m |
| 2'b | 2.23, m | 2.21, m | 2.23, m | |||
| 3' | 23.9 | 1.53, m | 24.2 | 1.53, m | 24.0 | 1.52, m |
| 4' | 30.6 | 1.25, m | 30.9 | 1.25, m | 30.5 | 1.24, m |
| 5' | 21.7 | 1.26, m | 22.0 | 1.26, m | 21.7 | 1.25, m |
| 6' | 13.7 | 0.84, t (7.0) | 13.9 | 0.83, t (7.1) | 13.9 | 0.84, t (7.1) |
| 12-OMe | – | – | – | – | 54.1 | 3.26, s |
| 1-OH | 4.74, d, (5.7) | 5.07, br s | 4.37, d (5.4) | |||
| 9-OH | 5.46, s | 4.41, br s | 4.93, s | |||
| 11-OH | – | 5.27, br s | – | |||
| 12-OH | – | 4.88, br s | – | |||
aAcquired at 150 MHz; bacquired at 600 MHz; cacquired at 125 MHz; dacquired at 500 MHz.
In vitro bioassay results for nanangenines 1–10.
| Compound | IC50 (μg mL−1)a | ||||
| Bsb | NS-1c | DU-145d | MCF-7e | Nfff | |
| >100 | >100 | >100 | >100 | >100 | |
| 62 ± 2 | 38 ± 1.5 | >100 | >100 | >100 | |
| 56 ± 6 | 0.16 ± 0.01 | 0.9 ± 0.2 | 0.19 ± 0.05 | 0.9 ± 0.1 | |
| 5.7 ± 0.1 | 4.1 ± 0.1 | >100 | >100 | >100 | |
| 9.4 ± 0.4 | 19 ± 2 | 37 ± 2 | 22 ± 1 | 37 ± 2 | |
| 4%g | 1.0 ± 0.1 | 32 ± 3 | 3.6 ± 0.4 | 2.1 ± 0.3 | |
| 2.3 ± 0.3 | 2.4 ± 0.1 | 15 ± 1 | 9.4 ± 0.7 | 6.8 ± 0.6 | |
| 78 ± 2 | 49 ± 2 | 95 ± 3 | 49 ± 1 | 84 ± 2 | |
| >100 | 47 ± 2 | >100 | >100 | >100 | |
| >100 | 10 ± 2 | 7%g | 62 ± 2 | 60 ± 1 | |
| control | 0.4h | 0.02i | 18i | 2i | 0.2i |
aExperiments were conducted in triplicate. IC50 values are mean ± standard error; bBacillus subtilis (ATCC 6633); cmouse myeloma NS-1 cell line (ATCC TIB-18); dhuman prostate cancer DU-145 cell line (ATCC HTB-81); eHuman breast adenocarcinoma MCF-7 cell line (ATCC HTB-22); fHuman fibroblast NFF cell line (ATCC PCS-201); gincomplete dose response, % inhibition reached at 100 μg mL−1; htetracycline; istaurosporine.
Figure 2Putative nanangenine biosynthetic gene cluster in A. nanangensis MST-FP2251 and homologs identified in other drimane sesquiterpenoid-producing species of Aspergillus section Usti. Gene models are drawn to scale; shaded boxes that link gene models represent amino acid identity (0% transparent; 100% black).
Figure 3Putative biosynthetic pathway to the nanangenines.